Long-term management of pediatric psoriasis with ixekizumab: a case report

Long-term management of pediatric psoriasis with ixekizumab: a case report

Psoriasis in pediatric patients is uncommon and the management of moderate-to-severe cases can be challenging. We report the case of a 17-year-old girl who presented with severe plaque psoriasis unresponsive to UVB phototherapy. The Psoriasis Area Severity Index (PASI) was 18 and the Dermatology Lif...

Full description

Bibliographic Details
Main Authors:	Diego Orsini, Luciano Ibba, Alessandra Narcisi, Pasquale Frascione, Alessia Pacifico, Mario Valenti, Antonio Costanzo, Luigi Gargiulo
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-12-01
Series:	Journal of Dermatological Treatment
Subjects:	ixekizumab pediatric psoriasis real-life
Online Access:	http://dx.doi.org/10.1080/09546634.2023.2198622

Similar Items

Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis)
by: Mario Valenti, et al.
Published: (2024-05-01)

Biologics for the Treatment of Severe Acrodermatitis Continua of Hallopeau: Report of Two Cases Successfully Treated with Ixekizumab and Ustekinumab
by: Luigi Gargiulo, et al.
Published: (2023-04-01)

Ixekizumab: an alternative for HIV-positive psoriasis patients
by: Fanghua Liu, et al.
Published: (2024-11-01)

Erythrodermic psoriasis after discontinuation of ixekizumab
by: Kathryn Anne Potter, MD, et al.
Published: (2018-01-01)

Ixekizumab as a successful treatment in pediatric generalized pustular psoriasis
by: Maria Esposito, et al.
Published: (2025-02-01)

Toxoplasmosis in a patient receiving ixekizumab for psoriasis
by: Yolanka Lobo, BPhysio, MBBS, et al.
Published: (2020-03-01)

Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers
by: Diego Orsini, et al.
Published: (2023-12-01)

Ixekizumab
by: İlgen Ertam Sağduyu
Published: (2022-04-01)

Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
by: Norman Wasel, et al.
Published: (2020-05-01)

Severe Generalized Pustular Psoriasis Successfully Treated with Ixekizumab: A Case Report
by: Martina Burlando, et al.
Published: (2022-11-01)

Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab
by: Hanley TL, et al.
Published: (2017-03-01)

Ixekizumab Improved Refractory Erythrodermic Psoriasis with Comorbid Diffuse Alopecia: A Case Report with 52-Week Follow-Up
by: Song B, et al.
Published: (2024-08-01)

A Comprehensive Review of Ixekizumab Efficacy in Nail Psoriasis from Clinical Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis
by: Bruce W. Kirkham, et al.
Published: (2023-07-01)

Ixekizumab is effective in the long-term management in moderate-to-severe plaque psoriasis: results from an Italian retrospective cohort study (the LOTIXE study)
by: Andrea Chiricozzi, et al.
Published: (2023-12-01)

Real-world evidence for ixekizumab in the treatment of psoriasis and psoriatic arthritis: literature review 2016–2021
by: Adam Reich, et al.
Published: (2023-12-01)

Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes
by: Luís Puig, et al.
Published: (2019-08-01)

Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy
by: Giunta A, et al.
Published: (2017-06-01)

Effectiveness of Ixekizumab in Elderly Patients for the Treatment of Moderate-to-Severe Psoriasis: Results From a Multicenter, Retrospective Real-Life Study in the Lazio Region
by: Annunziata Dattola, et al.
Published: (2024-07-01)

Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
by: Blauvelt A, et al.
Published: (2020-03-01)

Sustained Resolution of Nail Psoriasis Through 5 Years with Ixekizumab: A Post-Hoc analysis from UNCOVER-3
by: Alexander Egeberg, et al.
Published: (2022-10-01)

Impact of Ixekizumab Treatment on Itch and Psoriasis Area and Severity Index in Patients with Moderate-to-Severe Plaque Psoriasis: An Integrated Analysis of Two Phase III Randomized Studies
by: Gil Yosipovitch, et al.
Published: (2018-11-01)

Ixekizumab trough concentrations in psoriasis: Paving the way towards personalised therapy: A cohort study
by: Lisa Schots, et al.
Published: (2024-12-01)

Tineа Corporis with Trichophyton Rubrum Mimicking a Flare-Up of Psoriasis UnderTreatment with IL17-Inhibitor Ixekizumab
by: Vladimir Emelianov, et al.
Published: (2021-07-01)

Ixekizumab in the treatment of psoriatic arthritis
by: Yu. L. Korsakova, et al.
Published: (2024-12-01)

Clinical experience of using Ixekizumab in treatment of a female patient with severe psoriasis and psoriatic arthritis, resistant to the therapy
by: N. V. Kungurov, et al.
Published: (2021-06-01)

Emerging targeted therapies for plaque psoriasis – impact of ixekizumab
by: Kazemi T, et al.
Published: (2017-04-01)

Biologics for psoriasis patients under 18 years of age: Real-world evidence from the Chinese psoriasis real world evidence research group
by: Yu-Xin Zheng, et al.
Published: (2022-09-01)

Successful Treatment of Linear Psoriasis With the IL-17a-Antagonist Ixekizumab: A Case Report
by: Christov S, et al.
Published: (2025-01-01)

Lentiginous eruption in resolving psoriasis plaques during treatment with ixekizumab: a case report and review of the literature
by: Pablo Santa María, et al.
Published: (2017-10-01)

Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study
by: Luciano Ibba, et al.
Published: (2023-12-01)

Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
by: Alexander Egeberg, et al.
Published: (2023-01-01)

Corrigendum: Efficacy of ixekizumab in patients with moderate-to-severe plaque psoriasis and prediabetes or type 2 diabetes
by: Alexander Egeberg, et al.
Published: (2023-03-01)

Drug Survival Outcomes Associated with the Real-World Use of Ixekizumab, Secukinumab, Guselkumab, and Adalimumab for the Treatment of Plaque Psoriasis in China: A 52-Week Single-Center Retrospective Study
by: Li Y, et al.
Published: (2022-10-01)

Ixekizumab Survival in Heavily Pretreated Patients with Psoriasis: A Two-year Single-centre Retrospective Study
by: Shany Sherman, et al.
Published: (2020-12-01)

Ixekizumab Real-World Effectiveness at 24 Weeks in Patients with Psoriasis: Data from the United States Taltz Customer Support Program
by: Alice B. Gottlieb, et al.
Published: (2023-07-01)

Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial
by: Kristian Reich, et al.
Published: (2022-05-01)

The efficacy of the interleukin 17 inhibitor ixekizumab in psoriatic arthritis: data from real clinical practice
by: I. M. Marusenko, et al.
Published: (2021-06-01)

Time to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis
by: Kim Papp, et al.
Published: (2022-03-01)

Long-term Impact of Ixekizumab on Psoriasis Itch Severity: Results from a Phase III Clinical Trial and Long-term Extension
by: Alexandra B. Kimball, et al.
Published: (2017-10-01)

Rare Case Report of Primary Active Pulmonary Tuberculosis During Ixekizumab Treatment for Plaque Psoriasis
by: Li Y, et al.
Published: (2024-07-01)